Analysts back AstraZeneca's $2B Summit Therapeutics investment as stock gains

AstraZeneca's stock climbed 2.0% on September 29, 2026, following the company's announcement that it had invested $2 billion in Summit Therapeutics. Through this equity stake, AstraZeneca acquired roughly 12% of Summit's common stock via convertible preferred shares, trading at a premium of approximately $18.36 per share. The investment comes as a testament to AstraZeneca's confidence in ivonescimab, a novel bispecific antibody that targets both PD-1 and VEGF, signaling the drug as a key component of next-generation cancer therapies.

In addition to the equity investment, AstraZeneca and Summit Therapeutics entered into a clinical collaboration to evaluate the potential of combining AstraZeneca's ADC, sonesitatug vedotin, with ivonescimab in treating various gastrointestinal cancers. To further bolster their oncology pipeline, AstraZeneca also submitted a U.S. FDA New Drug Application for a combination of savolitinib and osimertinib in patients with MET-driven non-small cell lung cancer, backed by positive Phase III SAFFRON study results.

The market's overall performance was modestly supportive, with the FTSE 100 rising as UK retail price inflation decelerated to 1.4% in September, offering some relief to investor sentiment. However, factors such as rising oil prices, increasing UK gilt yields, and ongoing geopolitical tensions between the U.S. and Iran kept the index's gains from escalating further.

The combination of the $2 billion investment, the clinical collaboration, and the FDA NDA submission portrayed AstraZeneca's commitment to reinforcing its leadership in the oncology sector, leading to a significant rise in the company's share price to 12,738p during today's trading session, significantly above its opening price of 12,526p.